Replies to post #188216 on Biotech Values

[jq1234]

Barclay Propriety Rx Numbers from Mar 4, 2015:

Proprietary New Treatment Start data from AlphaImpactRx shows that Harvoni has a dominant 63% share across all patient genotypes, with Viekira Pak having captured a 15% share.

------

Harvoni captured 68-75% of Genotype 1 patients versus 14-21% for Viekira Pak during the last 3 weeks in January.